OT, Other biotechs:
Vphm, good short some time ago, but now is risky, Fda could approved their picovir (I do not think is approvable), but it could go $5 to $10 next march 19? with negative advisory comitted results, problem is that the opposite will send it to double. The Ceo is very astute and smart, If he could not pull the approval no one will. They have good cash (from debt)but they have it, it is a volatile situation, He even turn into contract retail for their partner Aventis.
Eln is good at $10 to $12 long (good at current prices, but is in distribution so one could wait for $12). Eln has cash close to $2 billion, drugs that could grow, and 20 to 50 biotech deals, they need only one success to double. The accounting problems are way overblown by media.
Ligand, I owned it below $10, out at $14 to $16(4 times, never short on it) I like their potential.
Many small ones that has being crushed: Rzym, dsco, nabi, epix, sprx, allp, pars. Very high risk, many small bets, to invest more with their progress (or to standstill with their delays and/or death.
And Biogen in the low $50s. (I like Medi, but overvalue). DNA under $50.
I rarely short stocks. |
